The Best is yet to come13 Apr 2022 15:16
The successful use of viral vector technology in the development of Oxford-AstraZeneca’s two-dose Covid-19 vaccine has raised public awareness of the role of immunotherapy in the treatment of diseases. Building on this, research scientists from the University of Oxford and the Ludwig Institute for Cancer Research are developing a new cancer vaccine that makes use of similar technology. The vaccine flags cancer-specific antigens to the immune system which causes an increase in the response of tumour-infiltrating T-cells. In a study of mouse tumour models, the vaccine was shown to increase the levels of anti-tumour T-cells infiltrating the tumours, and as such, improved the efficacy of cancer immunotherapy. The cancer vaccine is now being assessed in a Phase 1/2a clinical trial featuring 80 patients with non-small cell lung cancer. As Adrian Hill, Lakshmi Mittal and Family Professorship of Vaccinology and director of the Jenner Institute, University of Oxford puts it: “This new vaccine platform has the potential to revolutionise cancer treatment.� It would not surprise me if the 4D vaccine under NDA with Merck is following similar outcomes... An update on progress here could be explosive...
https://pharmaceuticalmanufacturer.media/pharmaceutical-industry-insights/latest-pharmaceutical-manufacturing-industry-insights/cancer-immunotherapy-the-best-is-yet-to-come/
Thanks to porky post on advfn